The Effect of Hydroxychloroquine on Non-Alcoholic Fatty Liver Disease among Rheumatoid Arthritis Patients

Abstract

Get full access to this article

View all access options for this article.

References

Younossi

. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol 2019; 70: 531–44.

Choi

, Lee

, Kim

. Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study. Clin Rheumatol 2020: Oct 19. doi: 10.1007/s10067-020-05456-y. Epub ahead of print. PMID:33078254.

Sakthiswary

, Chan

, Koh

. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal 2014;823763.

Chuah

K-H

, Chan

W-K

. Quantification of liver fat in NAFLD: available modalities and clinical significance. Curr Hepatol Rep 2019; 18: 492–502.

Sasso

, Beaugrand

, de Ledinghen

. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010 Nov; 36: 1825–35. doi: 10.1016/j.ultrasmedbio.2010.07.005. Epub 2010 Sep 27. PMID:20870345.

Rempenault

, Combe

, Barnetche

. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018; 77: 98–103.